Canel M, Taggart D, Sims A, Lonergan D, Waizenegger I, Serrels A. T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. elife. 2020;9: pubmed publisher

Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019;10:2141 pubmed publisher

Lau C, Tiniakou I, Perez O, Kirkling M, Yap G, Hock H, et al. Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells. J Exp Med. 2018;215:2265-2278 pubmed publisher

Dorta Estremera S, Chin R, Sierra G, Nicholas C, Yanamandra A, Nookala S, et al. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Res. 2018;78:5327-5339 pubmed publisher

Zhang Y, Li N, Suh H, Irvine D. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat Commun. 2018;9:6 pubmed publisher

Smith T, Moffett H, Stephan S, Opel C, Dumigan A, Jiang X, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. J Clin Invest. 2017;127:2176-2191 pubmed publisher

Williams J, Horton B, Zheng Y, Duan Y, Powell J, Gajewski T. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017;214:381-400 pubmed publisher

Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015;112:E5290-9 pubmed publisher

Dai M, Yip Y, Hellstrom I, Hellstrom K. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015;21:1127-38 pubmed publisher

Murphy J, Burey A, Beebe A, Gu D, Presta L, Merghoub T, et al. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood. 2014;123:2172-80 pubmed publisher

Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS ONE. 2013;8:e84927 pubmed publisher

Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med. 2013;11:215 pubmed publisher

Dai M, Wei H, Yip Y, Feng Q, He K, Popov V, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother. 2013;36:248-57 pubmed publisher

Manzke N, Akhmetzyanova I, Hasenkrug K, Trilling M, Zelinskyy G, Dittmer U. CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells. J Virol. 2013;87:6306-13 pubmed publisher

Kwong B, Gai S, Elkhader J, Wittrup K, Irvine D. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013;73:1547-58 pubmed publisher

Curran M, Kim M, Montalvo W, Al Shamkhani A, Allison J. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE. 2011;6:e19499 pubmed publisher

Taraban V, Rowley T, O Brien L, Chan H, Haswell L, Green M, et al. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol. 2002;32:3617-27 pubmed